Humacyte, Inc. (HUMA) Key Metrics
HUMA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $119.2M
- Enterprise value
- $142.7M
- P/E (TTM)
- —
- Forward P/E
- 35.8
- PEG ratio
- —
- Price / sales
- 56.2
- Price / book
- 5.0 10-yr median 21.7
- EV / EBITDA
- 4.3
- Dividend yield
- —
- Beta
- 2.44
HUMA key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsHUMA valuation Price multiples at each fiscal year-end price.
Price / sales
74.5
2025 · hover or tap a bar for each year
20192025
Price / book
48.9
2025 · hover or tap a bar for each year
20192025
Free cash flow yield−53.1 pts
−69.7%
2025 · hover or tap a bar for each year
20192025
HUMA returns How much profit the business earns on the capital it uses.
Return on assets+79.6 pts
−32.1%
2025 · hover or tap a bar for each year
20192025
Asset turnover
0.02
2025 · hover or tap a bar for each year
20192025
HUMA per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.01
2025 · hover or tap a bar for each year
20192025
Earnings per share
−$0.26
2025 · hover or tap a bar for each year
20192025
Free cash flow per share
−$0.67
2025 · hover or tap a bar for each year
20192025
Book value per share
$0.02
2025 · hover or tap a bar for each year
20192025
Dividends per share
$0.00
2025 · hover or tap a bar for each year
20192025
Shares outstanding+33.5%
158.2M
2025 · hover or tap a bar for each year
20192025
HUMA financial health Debt, liquidity and how easily interest is covered.
Debt / equity
20.86
2025 · hover or tap a bar for each year
20192025
Net debt+$42.7M
$14.3M
2025 · hover or tap a bar for each year
20192025
Current ratio+53.9%
3.69
2025 · hover or tap a bar for each year
20192025
Interest coverage
-9.5
2025 · hover or tap a bar for each year
20192025
Debt / assets+364.6%
0.56
2025 · hover or tap a bar for each year
20192025
HUMA efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding
39 days
2025 · hover or tap a bar for each year
20192025
Days of inventory
145 days
2025 · hover or tap a bar for each year
20192025
Days payables outstanding−173 days
106 days
2025 · hover or tap a bar for each year
20192025
Cash conversion cycle
79 days
2025 · hover or tap a bar for each year
20192025
Capex / revenue
43.4%
2025 · hover or tap a bar for each year
20192025
HUMA valuation history
Fiscal year-endToday7-year median
HUMA returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
HUMA debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
HUMA price vs earnings per share
Share price at year-endEPS (right axis)
HUMA key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $151.9M | $598.3M | $293.7M | $217.4M | — | — | — |
| Enterprise value | $166.3M | $569.9M | $270.7M | $115.6M | — | — | — |
| Price / sales | 74.5 | — | — | 138.9 | — | — | — |
| Price / book | 48.9 | — | 21.7 | 1.9 | — | — | — |
| EV / sales | 81.6 | — | — | 73.9 | — | — | — |
| EV / EBITDA | — | — | — | 47.3 | — | — | — |
| Earnings yield | −26.9% | −24.9% | −37.7% | −5.5% | — | — | — |
| Free cash flow yield | −69.7% | −16.7% | −25.7% | −33.2% | — | — | — |
| Dividend yield | 0.0% | 0.0% | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | — | 0.0% | — | — | — |
| Share price at fiscal year-end | $0.96 | $5.05 | $2.84 | $2.11 | $7.25 | $10.17 | — |
| Per share | |||||||
| Revenue per share | $0.01 | $0.00 | $0.00 | $0.02 | — | — | $0.06 |
| Earnings per share | −$0.26 | −$1.26 | −$1.07 | −$0.12 | — | — | −$0.83 |
| Operating cash flow per share | −$0.66 | −$0.83 | −$0.71 | −$0.69 | — | — | −$0.70 |
| Free cash flow per share | −$0.67 | −$0.84 | −$0.73 | −$0.70 | — | — | −$0.78 |
| Cash per share | $0.32 | $0.38 | $0.78 | $1.47 | — | — | $0.91 |
| Book value per share | $0.02 | −$0.44 | $0.13 | $1.13 | — | — | $1.28 |
| Tangible book value per share | $0.02 | −$0.44 | $0.13 | $1.13 | — | — | $1.28 |
| Dividends per share | $0.00 | $0.00 | — | — | — | — | — |
| Capex per share | $0.01 | $0.01 | $0.02 | $0.01 | — | — | $0.08 |
| Debt per share | $0.41 | $0.14 | $0.56 | $0.49 | — | — | $0.28 |
| Shares outstanding | 158.2M | 118.5M | 103.4M | 103.1M | — | — | 103.0M |
| Change in shares outstanding | +33.5% | +14.6% | +0.4% | — | — | — | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | — | — | −169.8% | −10.0% | −27.5% | −65.6% | −64.6% |
| Return on invested capital (ROIC) | — | — | — | — | — | −80.5% | −100.7% |
| Return on assets (ROA) | −32.1% | −111.8% | −66.6% | −4.9% | −13.5% | −48.3% | −50.6% |
| Return on tangible assets | −35.1% | −107.9% | −86.4% | −5.9% | −9.2% | −62.4% | −50.6% |
| Financial health | |||||||
| Total debt | $64.8M | $16.5M | $57.5M | $50.1M | $51.2M | $28.9M | $28.7M |
| Cash & short-term investments | $50.5M | $44.9M | $80.4M | $151.9M | $225.5M | $39.9M | $93.7M |
| Net debt | $14.3M | −$28.4M | −$23.0M | −$101.8M | −$174.3M | −$11.1M | −$65.0M |
| Debt / equity | 20.86 | — | 4.24 | 0.43 | 0.42 | 0.41 | 0.22 |
| Debt / assets | 0.56 | 0.12 | 0.45 | 0.25 | 0.18 | 0.27 | 0.17 |
| Net debt / EBITDA | — | — | — | −41.64 | — | — | — |
| Current ratio | 3.69 | 2.40 | 4.52 | 7.88 | 20.75 | 3.69 | 8.76 |
| Quick ratio | 2.95 | 2.40 | 4.52 | 7.88 | 20.75 | 3.69 | 8.76 |
| Interest coverage | -9.5 | -12.3 | -15.2 | -13.6 | -18.7 | -29.3 | -37.3 |
| Working capital | $49.4M | $27.9M | $64.8M | $134.6M | $218.3M | $30.2M | $84.1M |
| Invested capital | $17.5M | −$81.1M | −$9.4M | $15.1M | −$52.1M | $59.6M | $67.2M |
| Tangible asset value | $3.1M | −$52.7M | $13.5M | $116.9M | $122.2M | $70.7M | $132.2M |
| Net current asset value | −$45.5M | −$142.7M | −$31.4M | $66.8M | $65.0M | $5.4M | $58.5M |
| Graham net-net per share | −$0.35 | −$1.23 | −$0.33 | $0.63 | — | — | $0.56 |
| Capital allocation | |||||||
| Dividends paid | $0 | $0 | — | — | — | — | — |
| Share buybacks (net) | — | $0 | — | $0 | $0 | — | — |
| Capex / revenue | 43.4% | — | — | 67.0% | 17.4% | 21.3% | 131.3% |
| Capex / depreciation | 0.12 | 0.22 | 0.30 | 0.13 | 0.03 | 0.04 | 1.20 |
| Stock-based compensation / revenue | 478.6% | — | — | 395.1% | 803.3% | 314.8% | 72.0% |
| R&D / revenue | 3,400.5% | — | — | 4,042.2% | 4,856.8% | 3,627.0% | 1,222.0% |
| SG&A / revenue | 1,529.5% | — | — | 1,462.2% | 1,664.7% | 795.5% | 263.1% |
| Efficiency | |||||||
| Days sales outstanding | 39.5 | — | — | 24.1 | 41.8 | 87.4 | 35.5 |
| Days of inventory on hand | 145.5 | — | — | -0.7 | 0.0 | 0.0 | 0.0 |
| Days payables outstanding | 105.9 | 278.7 | 19.3 | 81.6 | 13.0 | 18.7 | 15.8 |
| Cash conversion cycle (days) | 79.0 | — | — | -58.1 | 28.8 | 68.7 | 19.7 |
| Receivables turnover | 9.24 | — | 0.00 | 15.12 | 8.74 | 4.18 | 10.29 |
| Payables turnover | 3.45 | 1.31 | 18.94 | 4.48 | 28.09 | 19.50 | 23.11 |
| Inventory turnover | 2.51 | — | — | — | 61,341,000.00 | 54,078,000.00 | 75,603,000.00 |
| Asset turnover | 0.02 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.04 |
| Average receivables | $220,500 | $0 | $15,500 | $103,500 | $144,500 | $357,000 | $601,000 |
| Average payables | $4.9M | $5.5M | $4.0M | $1.8M | $2.2M | $2.8M | $3.3M |
| Average inventory | $6.8M | $0 | — | −$15,500 | $1 | $1 | $1 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from HUMA's annual financial statements (latest annual report filed March 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
HUMA valuation and financial ratios
It ended the year with $64.8 million of debt and $50.5 million in cash and short-term investments, net debt of $14.3 million. The share count rose 53.5% from 103.0M to 158.2M over 6 years.
See the HUMA income statement, the HUMA chart for price history, or the HUMA stock overview for the latest quote and news.
HUMA key metrics FAQ
How much debt does Humacyte have?
Humacyte had total debt of $64.8 million at the end of fiscal 2025, a debt-to-equity ratio of 20.86.
Does Humacyte pay a dividend?
Humacyte did not pay a dividend in fiscal 2025.
What is Humacyte's free cash flow yield?
Humacyte generated -$105.9 million of free cash flow in fiscal 2025, a free cash flow yield of −69.7% on its market value at year-end ($151.9 million).
What is Humacyte's current ratio?
Humacyte's current ratio was 3.69 at the end of fiscal 2025: current assets were 3.69 times current liabilities.